<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986933</url>
  </required_header>
  <id_info>
    <org_study_id>CIM003JG</org_study_id>
    <nct_id>NCT01986933</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of CIM331 for Atopic Dermatitis Patients</brief_title>
  <official_title>A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic
      dermatitis patients who are inadequately controlled by or intolerant to topical therapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent improvement from baseline in pruritus Visual Analogue Scale (VAS)</measure>
    <time_frame>baseline to week12</time_frame>
    <description>Percent improvement from baseline in pruritus VAS at week12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>baseline to week12 (Part A), up to week64 (Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline in SCORing Atopic Dermatitis (SCORAD)</measure>
    <time_frame>baseline to week12 (Part A), up to week64 (Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline in static Investigator's Global Assessment (sIGA)</measure>
    <time_frame>baseline to week12 (Part A), up to week64 (Part B)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement from baseline in Body Surface Area (BSA) of AD involvement</measure>
    <time_frame>baseline to week12 (Part A), up to week64 (Part B)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Placebo Part B: nemolizumab (CIM331)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nemolizumab (CIM331)</intervention_name>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_label>Group3</arm_group_label>
    <arm_group_label>Group4</arm_group_label>
    <arm_group_label>Group5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Group5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 and ≤65 years of age at the time of consent.

          -  Patients with Atopic Dermatitis

          -  Pruritus visual analogue scale (VAS) ≥50 mm at the screening and baseline visit

          -  Eczema Area and Severity Index (EASI) ≥10 at the screening and baseline visit

          -  static Investigator's Global Assessment (sIGA) score ≥3 at the baseline visit

        Exclusion Criteria:

          -  Serological evidence of hepatitis B virus or hepatitis C virus infection

          -  Known human immunodeficiency virus infection

          -  Ongoing treatment with specific or non-specific hyposensitization therapy for AD

          -  Treatment with mild or moderately potent topical corticosteroids (TCS) within 1 week
             prior to randomization

          -  History of infection including skin infection requiring treatment with oral or
             intravenous (IV) antibiotics, antivirals, or antifungals within 1 week prior to
             randomization.

          -  Evidence of tuberculosis (TB) infection as defined by a positive purified protein
             derivative (PPD) and/or positive interferon-gamma release assay.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryosuke Mihara</last_name>
    <role>Study Director</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2013</study_first_posted>
  <last_update_submitted>July 4, 2016</last_update_submitted>
  <last_update_submitted_qc>July 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

